Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

WIXOM, Mich. , June 1, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on May 31, 2022 informing Rockwell Medical that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market.

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

WIXOM, Mich. , May 31, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it has entered into securities purchase agreements with Armistice Capital Master Fund Ltd.

Rockwell Medical Announces $15 Million At-Market Offering

WIXOM, Mich. , May 23, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that Russell Ellison, M.D.

Rockwell Medical, Inc. to Present at H.C. Wainwright Annual Global Life Sciences Conference

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q1 2022 Earnings Conference Call May 16, 2022 4:15 PM ET Company Participants Jason Finkelstein - Investor Relations Russell Ellison - President and Chief Executive Officer Russell Skibsted - Executive Vice President, Chief Financial Officer and Chief Business Officer Marc Hoffman - Chief Medical Officer Tim Chole - Senior Vice President, Sales and Marketing Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen and welcome to the Rockwell Medical First Quarter 2022 Results Call. [Operator Instructions] As a reminder, this conference call is being recorded.

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q1 2022 Results - Earnings Call Transcript

- First quarter net sales of $16.1 million, up 4.2% year-over-year -  - Submitted Supplemental Data to FDA for IND Application to enable Phase 2 FPC Home Infusion Trial - - Amended and expanded supply agreement with DaVita, including $7.5M investment, strengthens Rockwell's financial position, laying groundwork for profitable concentrates business - - Completion of patient enrollment ahead of schedule in pivotal Phase 3 trial of Triferic® in China - - Conference call and webcast scheduled for today at 4:15 p.m. ET - WIXOM, Mich.

Rockwell Medical Provides First Quarter 2022 Financial and Operational Update

Rockwell Medical Inc (NASDAQ: RMTI) has provided the FDA with the supplemental data requested by the agency in December 2021 for its pending Investigational New Drug (IND) application of Ferric Pyrophosphate Citrate (FPC) for iron deficiency. The IND supports the proposed Phase 2.

Rockwell Medical Submits Additional Data For IND Application For Iron Deficiency Candidate

WIXOM, Mich. , May 12, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it provided the U.S. Food and Drug Administration (FDA) with the supplemental data, requested by the agency in December 2021 , for the Company's pending Investigational New Drug (IND) application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

WIXOM, Mich., May 12, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that its Board of Directors has approved a 1-for-11 reverse split of the Company's issued and outstanding common stock (the "Reverse Stock Split").

Rockwell Medical Announces 1-for-11 Reverse Stock Split

WIXOM, Mich. , May 11, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, May 16 at 4:15 PM ET to discuss its financial results for the three months ended March 31, 2022, and recent operational highlights.

Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022

Trial with over 400 Patients Conducted by Partner Wanbang Pharmaceuticals, a Subsidiary of Fosun Pharma Over 600,000 Patients receive Hemodialysis in China WIXOM, Mich. , April 25, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that its partner, Wanbang Biopharmaceuticals enrolled the final patient, ahead of schedule, in its pivotal Phase 3 clinical trial for Triferic® (ferric pyrophosphate citrate) Dialysate to support a new drug application for regulatory approval in China.

Rockwell Medical Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic® in China

WIXOM, Mich. , April 20, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients, today announced that the company is scheduled to present at the Noblecon18, Noble Capital Market's 18th Annual Investor Conference in Hollywood, Florida, on Thursday, April 21 st at 10:00 AM ET.

Rockwell Medical to Present at Noblecon18 Investor Conference

Alset EHome International

SNDL Inc.

Exela Technologies

Penny stocks under $1 to watch in April 2022 The post Best Penny Stocks Today? 4 To Buy For Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks Today? 4 To Buy For Under $1

DaVita

$7.5M initial equity investment in Rockwell Amended and expanded supply agreement Strengthens Rockwell's financial position, laying groundwork for improved concentrate business WIXOM, Mich., April 11, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced an expanded partnership with DaVita Inc. (NYSE: DVA), a leading kidney care provider.

Rockwell Medical Expands Partnership with DaVita

- Limitations of Currently Available Therapies and Lack of Consensus Guidelines Lead to Suboptimal Treatment of Iron Deficiency Anemia - - Most Survey Respondents Expressed a Preference for an At-Home Infusion Versus a Visit to an Outpatient Infusion Center - - Survey Highlights to be Presented at the NHIA 2022 Annual Conference - WIXOM, Mich. and NASHVILLE, Tenn.

New Survey from Rockwell Medical Reveals Management of Iron Deficiency Anemia in Home Infusion Patients Does Not Adequately Address Medical Need

WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the National Home Infusion Association's (NHIA) 2022 Annual Conference, to be held March 12-16 in Nashville, Tennessee.

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association's 2022 Annual Conference

WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference, on Wednesday, February 23rd at 1:30 - 2:00 PM ET.

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company's Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company's common stock (the “Inducement Grant”). The Inducement Grant has been granted outside of the Company's Amended and Restated 2018 Long Term Incentive Plan (“Plan”), but remains subject to the terms and conditions of such Plan. The Inducement Grant was made as an inducement material to such individual entering into employment with Rockwell Medical in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price of $0.40, which is equal to the closing price of Rockwell Medical's common stock on February 10, 2022, the grant date of the award. The Inducement Grant will vest over a 3-year period, with one-third of the shares vesting on each of the first three anniversaries of the grant date, subject to continued employment through the applicable vesting dates.

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Two product forms of Triferic® are now approved in South Korea Two product forms of Triferic® are now approved in South Korea

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea

Vinco Ventures

TDH Hlds

Which penny stocks are on your watchlist right now? The post Here Are 3 Penny Stocks You Need to Know About in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here Are 3 Penny Stocks You Need to Know About in January

Rockwell Medical Inc's (NASDAQ: RMTI) partner, Jeil Pharmaceutical Co Ltd, has received regulatory approval in South Korea for Triferic Injection for iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical has an exclusive license agreement with Jeil to commercialize Triferic in South Korea.

Rockwell Medical Shares Surge On South Korean Approval For Iron Supplementation Therapy

The stock price of Rockwell Medical Inc (NASDAQ: RMTI) increased by over 40% during intraday trading today. This is why it happened.

Rockwell Medical Stock (RMTI): Why The Price Went Up Substantially Today

-Commercial launch expected in June/July 2022-

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea

WIXOM, Mich., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team is scheduled to present at the H.C. Wainwright BioConnect 2022 Conference.

Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference

WIXOM, Mich., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion

Rockwell Medical Inc (NASDAQ: RMTI) has announced the publication of results in the Journal of Bioequivalence & Bioavailability from a study evaluating the co-administration of intravenous (IV) Ferric Pyrophosphate Citrate (FPC, Triferic) with unfractionated heparin (UFH) as an admixture. The study demonstrated no clinically relevant drug-drug interaction (DDI) between FPC and UFH on the effects of UFH nor on the ability of FPC to deliver bioavailable iron when these agents are co-administered as a single admixture via an HD-machine syringe pump.

News for Rockwell Medical Stock (RMTI)